Nanobac Pharmaceuticals, Incorporated (NNBP)

0.0000 0.0000 (0.00%) At close: 01:15PM EDT

Nanobac Pharmaceuticals, Incorporated

3000 Bayport Drive
Suite 910
Tampa, FL 33607
United States
813-865-1125

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1

Key executives

Name	Title	Pay	Exercised	Year born
Mr. John M. Stanton	Chairman, CEO, CFO & Principal Accounting Officer	N/A	N/A	1963
Mr. Benedict Salvadore Maniscalco	Director of Clinical Research, Medical Director & Director	87.5k	N/A	1942
Dr. Neva Ciftcioglu	Co-Founder, Director of Science & Scientific Advisor	N/A	N/A	N/A
Dr. E. Olavi Kajander	Chief Science & Research Officer and MD of Nanobac OY	N/A	N/A	N/A

Amounts are as of 31 December 2007, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). It manufactures and markets in vitro diagnostic (IVD) kits, such as assays, antibodies, and reagents for detecting CNPs. The company's diagnostic assays comprise NANO-CAPTURE and NANO-SERO. Additionally, it conducts research and clinical studies in the development of urological diseases, including chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases, as well as cardiovascular diseases. Nanobac Pharmaceuticals, Incorporated was formerly known as HealthCentrics Inc. and changed its name to Nanobac Pharmaceuticals, Incorporated in December 2002. The company was founded in 1994 and is based in Tampa, Florida.

Corporate governance

Nanobac Pharmaceuticals, Incorporated’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.